HanAll BioPharma Co., Ltd. (009420.KS) Release: U.S. IND Accepted by the FDA in Support of the Clinical Development HL 007, a Unique Fixed Dose Combination to Treat Cardiovascular Disease
7/9/2010 5:09:00 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) Receives U.S. PTO Notice Of Allowance For Vitatropin(TM), Modified Human Growth Hormone
4/2/2010 12:32:03 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) Receives Issue Notification from the U.S. Patent and Trademark Office for its lead Hanferon(TM) (Protease resistant Interferon-alpha) Molecule
11/24/2009 1:17:32 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) Awarded $3.2 MM USD from the South Korean Government to Support Global Development of its Novel Hanferon(TM) SC Protein Therapeutic
7/21/2009 2:05:01 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) Acquires Global Rights To Nautilus Biotech's Protein Engineering Technology For Developing Novel Oral And Injectable Therapeutic Proteins
6/29/2009 1:49:11 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) And Yuhan Corporation Complete License Agreement For A Unique Cardiovascular Combination Product For The Korean Market
6/4/2009 12:56:43 PM
More...
|
Han All Pharmaceutical Co., Ltd. (009420.KS) to Present its Oral and Injectable Protein Therapeutic Program at 2009 Biotechnology Industry Organization (BIO) International Conference
5/14/2009 3:05:12 PM
More...
|
Nautilus Biotech and Han All Pharmaceutical Co., Ltd. (009420.KS) Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea
3/6/2007 1:15:53 PM
More...
|
Atrix Laboratories, Inc. (ATRX) Licenses Prostate Cancer Products In Korea
10/19/2005 5:09:49 PM
More...
|